Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cardiovascular disease

Cardiovascular disease

POU class 1 homeobox 1 (POU1F1; PIT1)

Cell culture and mouse studies suggest spironolactone could help prevent calcification of vascular and other soft tissues, which is seen in patients who have chronic kidney disease (CKD). In a mouse model of soft tissue calcification, spironolactone decreased tissue calcification and Pit1-mediated osteoinductive signaling compared with vehicle. In human aortic smooth muscle cells, spironolactone and PIT1-targeted small interfering RNA both decreased PIT1-mediated osteoinductive signaling compared with vehicle or control siRNA. Next steps include a prospective clinical trial to determine whether patients with CKD receiving spironolactone or another mineralocorticoid receptor antagonist have less tissue calcification and fewer cardiovascular complications than placebo-treated patients.
Spironolactone is a generic mineralocorticoid receptor antagonist and is used as a diuretic in patients who have cardiovascular diseases.

SciBX 6(4); doi:10.1038/scibx.2013.86
Published online Jan. 31, 2013

Patent application filed; available for licensing

Voelkl, J. et al. J. Clin. Invest.; published online Jan. 9, 2013;
doi:10.1172/JCI64093
Contact: Florian Lang, University of Tuebingen, Tuebingen, Germany
e-mail:
florian.lang@uni-tuebingen.de